Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

832

HTML

7924

Figures (1-1)

292

Tables (1-4)

306

Sum=9354

Publishing Process of This Article

Item

Count

Browse

1240

Download

1040

Sum=2280

Dec 28, 2013 (publication date) through Jan 22, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 28, 2013; 19(48): 9156-9173
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9156

Figure 1 Functional active groups of tacrolimus.

Citation: Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, Provenzani A, Polidori C, Vizzini G, Polidori P, D’Alessandro N. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013; 19(48): 9156-9173
URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9156.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9156